Garenoxacin

From Wikipedia, the free encyclopedia


Garenoxacin
Systematic (IUPAC) name
1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid
Identifiers
CAS number	91421-42-0
ATC code	J01MA19
PubChem	124093
Chemical data
Formula	C₂₃H₂₀F₂N₂O₄
Mol. mass	426.412 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral

Garenoxacin (INN) is a quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections.

It was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, excepf for Japan, South Korea, and China.

On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration has accepted the New Drug Application (NDA) for garenoxacin, and has been granted a 10-month review.^[1]

[edit] References

^ Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review. Retrieved on 2008-03-25.

v • d • e Antibacterials for systemic use: quinolones (J01M)

Fluoroquinolones	Alatrofloxacin^‡ • Ciprofloxacin • Danofloxacin^§ • Difloxacin^§ • Enoxacin • Enrofloxacin^§ • Fleroxacin^‡ • Garenoxacin • Gatifloxacin • Gemifloxacin • Grepafloxacin^‡ • Ibafloxacin^§ • Levofloxacin • Lomefloxacin • Marbofloxacin^§ • Moxifloxacin • Norfloxacin • Ofloxacin • Orbifloxacin^§ • Pazufloxacin • Pefloxacin • Pradofloxacin^§ • Prulifloxacin • Rufloxacin • Sarafloxacin^§ • Sitafloxacin^† • Sparfloxacin • Temafloxacin^‡ • Tosufloxacin • Trovafloxacin^‡

Other quinolones	Cinoxacin • Flumequine^§ • Nalidixic acid • Oxolinic acid • Pipemidic acid • Piromidic acid • Rosoxacin

^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§ Veterinary use medications.